155 BOVET RD., SUITE 303, SAN MATEO, CA
Other Events
Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Investor Presentation
Executive Compensation Granted to David Happel, Thierry Chauche, and Elizabet...
Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences Inc. Enters Underwriting Agreement for $164.5M Offering
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Submission Upload
Correspondence